CA3231192A1 - Pharmaceutical composition and use thereof - Google Patents

Pharmaceutical composition and use thereof Download PDF

Info

Publication number
CA3231192A1
CA3231192A1 CA3231192A CA3231192A CA3231192A1 CA 3231192 A1 CA3231192 A1 CA 3231192A1 CA 3231192 A CA3231192 A CA 3231192A CA 3231192 A CA3231192 A CA 3231192A CA 3231192 A1 CA3231192 A1 CA 3231192A1
Authority
CA
Canada
Prior art keywords
rng
acceptable salt
pharmaceutically acceptable
furmonertinib
furrnonertinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231192A
Other languages
English (en)
French (fr)
Inventor
Huibing Luo
Qing Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Pharmaceuticals Inc
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Publication of CA3231192A1 publication Critical patent/CA3231192A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3231192A 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof Pending CA3231192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2021/117692 WO2023035223A1 (zh) 2021-09-10 2021-09-10 药物组合物及其用途
CNPCT/CN2021/117692 2021-09-10
PCT/CN2022/086053 WO2023035611A1 (en) 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
CA3231192A1 true CA3231192A1 (en) 2023-03-16

Family

ID=85507161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231192A Pending CA3231192A1 (en) 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof

Country Status (10)

Country Link
US (1) US20240366600A1 (https=)
EP (1) EP4398909A4 (https=)
JP (1) JP2024533423A (https=)
KR (1) KR20240074779A (https=)
CN (1) CN117957000A (https=)
AU (1) AU2022341942A1 (https=)
CA (1) CA3231192A1 (https=)
IL (1) IL311331A (https=)
MX (1) MX2024002822A (https=)
WO (2) WO2023035223A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
JP2025510910A (ja) * 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116478138A (zh) * 2023-04-21 2023-07-25 江苏艾力斯生物医药有限公司 一种甲磺酸伏美替尼原料药的结晶方法
CN116893086A (zh) * 2023-04-28 2023-10-17 江苏艾力斯生物医药有限公司 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法
CN117547536A (zh) * 2023-11-15 2024-02-13 江苏艾力斯生物医药有限公司 一种药物组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN110590749B (zh) * 2016-03-07 2020-11-06 上海艾力斯医药科技股份有限公司 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用

Also Published As

Publication number Publication date
CN117957000A (zh) 2024-04-30
KR20240074779A (ko) 2024-05-28
AU2022341942A1 (en) 2024-05-02
EP4398909A1 (en) 2024-07-17
IL311331A (en) 2024-05-01
EP4398909A4 (en) 2025-08-13
WO2023035223A1 (zh) 2023-03-16
WO2023035611A1 (en) 2023-03-16
JP2024533423A (ja) 2024-09-12
US20240366600A1 (en) 2024-11-07
MX2024002822A (es) 2024-05-03

Similar Documents

Publication Publication Date Title
US20240366600A1 (en) Pharmaceutical compositions and use thereof
CN113710658A (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
JPWO2013058294A1 (ja) 膵臓癌及び／又は胆道癌治療薬
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
US20250017927A1 (en) Pharmaceutical composition and use thereof
US20220193066A1 (en) Quinoline derivative used for combination treatment of small cell lung cancer
CN116723858A (zh) 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法
WO2024061203A1 (en) Pharmaceutical composition and use thereof
JP7571053B2 (ja) 軟部肉腫の併用療法用キノリン誘導体
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
HK40110967A (zh) 药物组合物及其用途
HK40116696A (zh) 药物组合物及其用途
WO2022171064A1 (zh) 烟酰胺及含有其的组合物的制药用途
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer
HK40067323A (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250331

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260407

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260413

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260413

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260413

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260413